ClinicalTrials.gg
CompletedNCT01634555Updated Feb 26, 2019Results posted

A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI

A Phase 2 interventional study of Ramucirumab (IMC-1121B) and Irinotecan in Solid Tumors, sponsored by Eli Lilly and Company. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-26.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the effect of concomitant ramucirumab (IMC-1121B) on the pharmacokinetics of irinotecan and its metabolite SN-38 when coadministered with folinic acid and 5-fluorouracil, in participants with advanced malignant solid tumors resistant to standard therapy or for which no standard therapy is available.

02

Conditions studied

  • Solid Tumors

Keywords

  • Advanced Malignant Solid Tumors
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has histologic or cytologic documentation of a malignant solid tumor
  • Has an advanced solid tumor that is resistant to standard therapy or for which no standard therapy is available
  • Has resolution to Grade ≤1, per the National Cancer Institute , Version 4.0 (NCI-CTCAE v. 4.0), of all toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy
  • Has an (ECOG) performance status of 0-2
  • Has adequate hematologic, coagulation, and hepatic function
  • Has serum creatinine ≤ 1.5 x (ULN)
  • Urinary protein is \<2+ on dipstick or routine urinalysis (UA) at study entry
  • Women with must have a negative serum or urine pregnancy test
  • Eligible participants of (both sexes) agree to use adequate method of during the study period and for 12 weeks after the last dose of study medication

Exclusion criteria

Exclusion Criteria:

  • Has received a therapeutic monoclonal antibody within the last 42 days
  • Has received cytotoxic chemotherapy within the last 21 days
  • Has received radiotherapy within the last 14 days
  • Are currently enrolled in, or discontinued within the last 14 days from, a clinical trial involving an product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism during the last 3 months
  • Has an uncontrolled illness, including, but not limited to uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders
  • Has experienced any arterial thromboembolic event within the last 6 months
  • Has known or or uncontrolled spinal cord compression
  • Has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy
  • Has known infection or acquired immunodeficiency syndrome-related illness
  • Has received a prior organ or transplantation
  • Has undergone major surgery within the last 28 days
  • Has had a serious nonhealing wound, ulcer, or bone fracture within the last 28 days
  • Has an elective or planned major surgery to be performed during the course of the trial
  • Has a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection, Crohn's disease, ulcerative colitis, or chronic diarrhea
  • Has experienced a Grade 3 or higher bleeding event within the last 3 months
  • Has a known history or clinical evidence of Gilbert's Syndrome, or is known to have any of the following genotypes: uridine diphosphate glucuronosyltransferase isoform 1A1 (UGT1A1)*6/*6, UGT1A1*28/*28, or UGT1A1*6/*28
  • Has received inhibitors or inducers of cytochrome P (CYP) 450 /5 or CYP2C9 and/or isoenzymes within the last 3 weeks
  • Has cirrhosis at a level of B (or worse), or cirrhosis and a history of hepatic encephalopathy, or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    ramucirumab (IMC-1121B) and FOLFIRI

    Treatment is sequential, Ramucirumab (IMC-1121B) will be administered before FOLFIRI ((Irinotecan + Folinic acid + 5-Fluorouracil). FOLFIRI will be administered each cycle and Ramucirumab (IMC-1121B) will be administered beginning from Cycle 2 (2-week cycle).

    Biological: Ramucirumab (IMC-1121B) · Drug: Irinotecan · Drug: Folinic acid · Drug: 5-Fluorouracil

Interventions

  • Ramucirumab (IMC-1121B) 8 milligrams per kilogram (mg/kg), administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle (except Cycle 1)

    Also known as: IMC-1121B, LY3009806

  • 180 milligrams per square meter (mg/m²) administered IV on Day 1 of each cycle

  • 400 mg/m² administered IV on Day 1 of each cycle

  • 400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Dose-Normalized Area Under the Concentration Versus Time Curve of Irinotecan and Its Metabolite SN-38 From Time Zero to Infinity [AUC(0-∞)] in Cycle 1

    Dose-normalized AUC(0-∞) was calculated from AUC(0-∞) divided by the dose. Data presented are Geometric Least Squares (Geo LS) means. Geo LS means were adjusted for cycle, participant and random error.

    Time frame: Cycle 1: 0, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 22, 25, 28, 31, 34, 48, 72, 96 and 168 hours post-irinotecan infusion

  2. Pharmacokinetics: Dose-Normalized AUC(0-∞) of Irinotecan and Its Metabolite SN-38 in Cycle 2

    Dose-normalized AUC(0-∞) was calculated from AUC(0-∞) divided by the dose. Data presented are Geo LS means. Geo LS means were adjusted for cycle, participant and random error.

    Time frame: Cycle 2: 0, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 22, 25, 28, 31, 34, 48, 72, 96 and 168 hours post-irinotecan infusion

  3. Pharmacokinetics: Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Irinotecan and Its Metabolite SN-38 in Cycle 1

    Dose-normalized Cmax was calculated from Cmax divided by the dose. Data presented are Geo LS means. Geo LS means were adjusted for cycle, participant and random error.

    Time frame: Cycle 1: 0, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 22, 25, 28, 31, 34, 48, 72, 96 and 168 hours post-irinotecan infusion

  4. Pharmacokinetics: Dose-Normalized Cmax of Irinotecan and Its Metabolite SN-38 in Cycle 2

    Dose-normalized Cmax was calculated from Cmax divided by the dose. Data presented are Geo LS means. Geo LS means were adjusted for cycle, participant and random error.

    Time frame: Cycle 2: 0, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 22, 25, 28, 31, 34, 48, 72, 96 and 168 hours post-irinotecan infusion

Secondary outcomes

  1. Pharmacokinetics: Cmax of Ramucirumab (IMC-1121B)

    Time frame: Cycle 2: -2, -1, -0.5, 0, 2, 3, 4, 5, 8, 10, 25, 48, 72, 96, 168, 264, 336 hours post-ramucirumab (IMC-1121B) infusion

  2. Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)

    Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group.

    Time frame: Up To 2 Years

07

Results

Posted Jul 14, 2014

Participant flow

Participant flow — Overall Study
MilestoneRamucirumab (IMC-1121B) and FOLFIRI
Started29
Received at least 1 dose of study drug29
Drug-drug interaction (ddi) population25
Completed25
Not completed4
Withdrew: Adverse event3
Withdrew: Physician decision1

Outcome measures

PrimaryPharmacokinetics: Dose-Normalized Area Under the Concentration Versus Time Curve of Irinotecan and Its Metabolite SN-38 From Time Zero to Infinity [AUC(0-∞)] in Cycle 1

Dose-normalized AUC(0-∞) was calculated from AUC(0-∞) divided by the dose. Data presented are Geometric Least Squares (Geo LS) means. Geo LS means were adjusted for cycle, participant and random error.

Time frame:
Cycle 1: 0, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 22, 25, 28, 31, 34, 48, 72, 96 and 168 hours post-irinotecan infusion
Reported as:
Least squares mean · nanograms*hour/milliliter/milligram
Pharmacokinetics: Dose-Normalized Area Under the Concentration Versus Time Curve of Irinotecan and Its Metabolite SN-38 From Time Zero to Infinity [AUC(0-∞)] in Cycle 1
nanograms*hour/milliliter/milligramFOLFIRI (Cycle 1)
Irinotecan22.12 (19.72 to 24.82)
Metabolite SN-380.81 (0.70 to 0.93)
PrimaryPharmacokinetics: Dose-Normalized AUC(0-∞) of Irinotecan and Its Metabolite SN-38 in Cycle 2

Dose-normalized AUC(0-∞) was calculated from AUC(0-∞) divided by the dose. Data presented are Geo LS means. Geo LS means were adjusted for cycle, participant and random error.

Time frame:
Cycle 2: 0, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 22, 25, 28, 31, 34, 48, 72, 96 and 168 hours post-irinotecan infusion
Reported as:
Least squares mean · nanograms*hour/milliliter/milligram
Pharmacokinetics: Dose-Normalized AUC(0-∞) of Irinotecan and Its Metabolite SN-38 in Cycle 2
nanograms*hour/milliliter/milligramRamucirumab + FOLFIRI (Cycle 2)
Irinotecan20.56 (18.33 to 23.06)
Metabolite SN-380.77 (0.67 to 0.89)
Statistical analysis
  • Ramucirumab + FOLFIRI (Cycle 2) · Mixed Models Analysis · Ratio of geo ls means: 0.93 · 90% CI 0.83 to 1.05Ratio of Geo LS mean is AUC(0-∞) of Cycle 2/Cycle 1 for Irinotecan .
  • Ramucirumab + FOLFIRI (Cycle 2) · Mixed Models Analysis · Ratio of geo ls means: 0.95 · 90% CI 0.88 to 1.04Ratio of Geo LS mean is AUC(0-∞) of Cycle 2/Cycle 1 for Metabolite SN-38.
PrimaryPharmacokinetics: Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Irinotecan and Its Metabolite SN-38 in Cycle 1

Dose-normalized Cmax was calculated from Cmax divided by the dose. Data presented are Geo LS means. Geo LS means were adjusted for cycle, participant and random error.

Time frame:
Cycle 1: 0, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 22, 25, 28, 31, 34, 48, 72, 96 and 168 hours post-irinotecan infusion
Reported as:
Least squares mean · nanograms/milliliter/milligram
Pharmacokinetics: Dose-Normalized Maximum Observed Drug Concentration (Cmax) of Irinotecan and Its Metabolite SN-38 in Cycle 1
nanograms/milliliter/milligramFOLFIRI (Cycle 1)
Irinotecan3.18 (2.91 to 3.48)
Metabolite SN-380.05 (0.04 to 0.06)
PrimaryPharmacokinetics: Dose-Normalized Cmax of Irinotecan and Its Metabolite SN-38 in Cycle 2

Dose-normalized Cmax was calculated from Cmax divided by the dose. Data presented are Geo LS means. Geo LS means were adjusted for cycle, participant and random error.

Time frame:
Cycle 2: 0, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 22, 25, 28, 31, 34, 48, 72, 96 and 168 hours post-irinotecan infusion
Reported as:
Least squares mean · nanograms/milliliter/milligram
Pharmacokinetics: Dose-Normalized Cmax of Irinotecan and Its Metabolite SN-38 in Cycle 2
nanograms/milliliter/milligramRamucirumab + FOLFIRI (Cycle 2)
Irinotecan3.31 (3.02 to 3.62)
Metabolite SN-380.05 (0.04 to 0.06)
Statistical analysis
  • Ramucirumab + FOLFIRI (Cycle 2) · Mixed Models Analysis · Ratio of geo ls means: 1.04 · 90% CI 0.97 to 1.12Ratio of Geo LS mean is Cmax of Cycle 2/Cycle 1 for Irinotecan.
  • Ramucirumab + FOLFIRI (Cycle 2) · Mixed Models Analysis · Ratio of geo ls means: 0.97 · 90% CI 0.85 to 1.12Ratio of Geo LS mean is Cmax of Cycle 2/Cycle 1 for Metabolite SN-38.
SecondaryPharmacokinetics: Cmax of Ramucirumab (IMC-1121B)
Time frame:
Cycle 2: -2, -1, -0.5, 0, 2, 3, 4, 5, 8, 10, 25, 48, 72, 96, 168, 264, 336 hours post-ramucirumab (IMC-1121B) infusion
Reported as:
Geometric mean · micrograms/milliliter (µg/mL)
Pharmacokinetics: Cmax of Ramucirumab (IMC-1121B)
micrograms/milliliter (µg/mL)Ramucirumab + FOLFIRI (Cycle 2)
Pharmacokinetics: Cmax of Ramucirumab (IMC-1121B)201.6 ± 31
SecondaryNumber of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)

Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group.

Time frame:
Up To 2 Years
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)
ParticipantsRamucirumab + FOLFIRI (Cycle 2)
Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)0

Adverse events

Collected over Up To 2 Years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ramucirumab (IMC-1121B) and FOLFIRI—11/29 (37.9%)28/29 (96.6%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventRamucirumab (IMC-1121B) and FOLFIRI
PneumoniaInfections and infestations3/29
DehydrationMetabolism and nutrition disorders2/29
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/29
Respiratory failureRespiratory, thoracic and mediastinal disorders2/29
AscitesGastrointestinal disorders1/29
Colonic fistulaGastrointestinal disorders1/29
DiarrhoeaGastrointestinal disorders1/29
Gastrointestinal haemorrhageGastrointestinal disorders1/29
Large intestinal obstructionGastrointestinal disorders1/29
Small intestinal obstructionGastrointestinal disorders1/29
Most frequent other events
Showing 10 of 85
Most frequent other events
EventRamucirumab (IMC-1121B) and FOLFIRI
FatigueGeneral disorders21/29
DiarrhoeaGastrointestinal disorders20/29
NauseaGastrointestinal disorders17/29
AnaemiaBlood and lymphatic system disorders15/29
NeutropeniaBlood and lymphatic system disorders15/29
Abdominal painGastrointestinal disorders15/29
Decreased appetiteMetabolism and nutrition disorders15/29
HypoalbuminaemiaMetabolism and nutrition disorders14/29
ConstipationGastrointestinal disorders12/29
Mucosal inflammationGeneral disorders11/29

Baseline characteristics

All enrolled participants who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Ramucirumab (IMC-1121B) and FOLFIRI
<=18 years0
Between 18 and 65 years19
>=65 years10
Sex: Female, Male
Sex: Female, Male(Participants)Ramucirumab (IMC-1121B) and FOLFIRI
Female14
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ramucirumab (IMC-1121B) and FOLFIRI
Hispanic or Latino1
Not Hispanic or Latino26
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ramucirumab (IMC-1121B) and FOLFIRI
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White24
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(Participants)Ramucirumab (IMC-1121B) and FOLFIRI
United States29
08

Study locations

5 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Detroit, Michigan 48202, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Las Vegas, Nevada 89169, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Cleveland, Ohio 44195, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Philadelphia, Pennsylvania 19111, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Pittsburgh, Pennsylvania 15213, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Aug 2013 and a completion of Feb 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2012
First posted
Jul 6, 2012
Start
Oct 2012
Primary completionActual
Aug 2013
CompletionActual
Feb 2018
Results first posted
Jul 14, 2014
Last update
Feb 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01634555
Responsible party
Sponsor
First posted
Jul 6, 2012
Start date
Oct 2012
Primary completion
Aug 2013
Completion
Feb 2018
Results posted
Jul 14, 2014
Last update
Feb 26, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ramucirumab · Irinotecan · Leucovorin · Fluorouracil

Start the discussion